Manuela Arbune1, Costinela Georgescu2. 1. Department of Morphological Sciences, Dunarea de Jos University Faculty of Medicine and Pharmacy, Galati, Romania. 2. Department of Pharmaceutical Sciences, Dunarea de Jos University Faculty of Medicine and Pharmacy, Galati, Romania.
Abstract
BACKGROUND: Infection with hepatitis B virus (HBV) contributes to morbidity and mortality in people living with human immunodeficiency virus (HIV). AIMS: The aim of the present study is to assess the influence of HBV co-infection in clinical characteristics and disease evolution among nosocomial HIV infected youth in Romania. STUDY DESIGN: Retrospective study. METHODS: We assessed HBsAg in 179 young people with nosocomial paediatric HIV infection. Demographic data, ALAT level, CD4-count, HIV-RNA, antiretroviral therapy and clinical behaviour were all statistically compared in patients who were HIV mono-infected and HBV-co-infected. RESULTS: THE CHARACTERISTICS OF PATIENTS ARE AS FOLLOWS: sex ratio M/F: 55.3%, AIDS category 88%, median nadir CD4-count 126/mm(3). The prevalence of persistent HBsAg was 44.6%. The mortality rate was 11.1%, but no correlation with HBsAg was found. An average of three antiretroviral combinations is experienced by 97.7% of patients, including Lamivudine for over 5 years in 76% of cases and Tenofovir/Emtricitabine in 16.75% of patients. Patients under antiretroviral therapy achieved 53.07% sustained undetectable HIV-RNA and 40.78% restored immunity CD4-count >500/mm(3). ALAT enzyme was found to be high in 54.75% of patients. CONCLUSION: During our research, we noticed that HBsAg was elevated in young people with HIV in Romania. Mortality rate was not statistically correlated to HBsAg. High ALAT levels are related with HBV, HDV co-infections, virological failure to antiretroviral treatment and the risk of death.
BACKGROUND: Infection with hepatitis B virus (HBV) contributes to morbidity and mortality in people living with human immunodeficiency virus (HIV). AIMS: The aim of the present study is to assess the influence of HBV co-infection in clinical characteristics and disease evolution among nosocomial HIV infected youth in Romania. STUDY DESIGN: Retrospective study. METHODS: We assessed HBsAg in 179 young people with nosocomial paediatric HIV infection. Demographic data, ALAT level, CD4-count, HIV-RNA, antiretroviral therapy and clinical behaviour were all statistically compared in patients who were HIV mono-infected and HBV-co-infected. RESULTS: THE CHARACTERISTICS OF PATIENTS ARE AS FOLLOWS: sex ratio M/F: 55.3%, AIDS category 88%, median nadir CD4-count 126/mm(3). The prevalence of persistent HBsAg was 44.6%. The mortality rate was 11.1%, but no correlation with HBsAg was found. An average of three antiretroviral combinations is experienced by 97.7% of patients, including Lamivudine for over 5 years in 76% of cases and Tenofovir/Emtricitabine in 16.75% of patients. Patients under antiretroviral therapy achieved 53.07% sustained undetectable HIV-RNA and 40.78% restored immunity CD4-count >500/mm(3). ALAT enzyme was found to be high in 54.75% of patients. CONCLUSION: During our research, we noticed that HBsAg was elevated in young people with HIV in Romania. Mortality rate was not statistically correlated to HBsAg. High ALAT levels are related with HBV, HDV co-infections, virological failure to antiretroviral treatment and the risk of death.
Authors: C Apetrei; I Loussert-Ajaka; G Collin; F Letourneur; M Duca; S Saragosti; F Simon; F Brun-Vézinet Journal: AIDS Res Hum Retroviruses Date: 1997-03-01 Impact factor: 2.205
Authors: Gail V Matthews; Prince Manzini; Zonghui Hu; Paul Khabo; Patrick Maja; Gugu Matchaba; Phumele Sangweni; Julie Metcalf; Nicholaas Pool; Susan Orsega; Sean Emery Journal: AIDS Date: 2011-09-10 Impact factor: 4.177
Authors: Jennifer Audsley; Philipp du Cros; Zachary Goodman; Catriona McLean; Anne Mijch; Sharon R Lewin; Joe Sasadeusz Journal: J Med Virol Date: 2012-07 Impact factor: 2.327
Authors: Simona Maria Ruta; Rodica Floarea Matusa; Camelia Sultana; Loredana Manolescu; Claudia A Kozinetz; Mark W Kline; Costin Cernescu Journal: J Int AIDS Soc Date: 2005-03-25 Impact factor: 5.396